170 likes | 177 Vues
PRESENTATION ON BRAND INDIA PROMOTION. By Ashutosh Gupta COA Member -Pharmexcil Executive Director -Medicamen Biotech Ltd . Email : guptaashutosh@medicamen.com. INTRODUCTION TO SME’S. Gross Capital Below 5 Crores. 2. Top Management comprises of 2-3 individuals in most cases.
E N D
PRESENTATION ON BRAND INDIA PROMOTION By Ashutosh Gupta COA Member -Pharmexcil Executive Director -Medicamen Biotech Ltd. Email : guptaashutosh@medicamen.com
INTRODUCTION TO SME’S • Gross Capital Below 5 Crores. • 2. Top Management comprises of 2-3 individuals in most cases. • 3.Limited resources. • 4.Lack of protection and minimal chances of Bailout. • 5.Good source for employment. • 6.Lack of automation. • 7.Generic Sales / Lack of profitability.
IMPORTANCE OF BRAND INDIA 1.Goes a long way to help SME’S for better exports. 2. Better acceptability of Products & Companies. 3. Better Margins. 4. Better Brand Positioning w.r.t. CHINA. 5.More investments and JV’S. 6.Big opportunity awaiting in 2012 in terms of patents expiring.
BRAND INDIA PROMOTION • Special programes to upgrade the industry image abroad as well as inside the country. • Pharmacopeal leverage. • India’s own Pharma expo in India as well as abroad. • Cooperative agreements with FDA’s. • Provision of easy finance. • Incentive to SME’s for entry into regulated markets. • Task should be shared with indians abroad. • Need for comprehensive package for the industry.
SPECIAL PROGRAMMES TO • UPGRADE THE INDUSTRYIMAGE • Trust building of our Government towards our Industry. • Road shows abroad. • Specific Ministerial delegations. • Special diplomatic task force. • Designated technical official in important markets in embassies.
2. PHARMACOPEAL LEVERAGE • IP is today at par with BP. • COPP’s • Brand image of Pharmacopia. • Leap jump ahead of china. • Cost effectiveness. • Better Documentation. • Better Product Range.
3. INDIA’S OWN PHARMA EXPO • Show of strength. • We will come at par with other industries. • We reach all parts of the world. • Better exposure. • International Participations.
4. COOPERATIVE AGREEMENTSwith FDA’s • Better Brand image. • Time saving. • Cost effective • Makes way for FDI’S and JV’S. • Pharmacopeal leverage. • Increase in exports.
5 PROVISION OF EASY FINANCE • SME’S always struggle due to lack of finance. • If finance is available more exports can be attained. • Easy upgradation towards CGMP/GLP. • Concentrated effort on exports. • Brand building of products. • Better image of Indian industry.
6. INCENTIVES TO SME’S FOR ENTRY INTO REGULATED MARKETS • Huge finance required. • Bioequivalence • Validations. • CTD Dossiers. • Trained regualatory staff. • Huge gestation period. • Scope of profitability. • Better number in US and EUROPE. • Jump in exports. • Better brand image. • Long lasting effects.
7.TASK SHOULD BESHARED WITH INDIANS ABROAD • Enrolment as associate members. • Most of Indians are well established . • They will feel more attatched. • Broad vision from the markets perspective. • First hand information. • Provides vast scope for improvement. • More Effective Buyer seller meet in India and abroad. • Better representation in terms of brand India. • We meet good buyers resulting in growth of exports.
8. COMPREHENSIVEPACKAGE • NEED • International conditions are very volatile. • Regulatory authorities becoming more stricter day by day. • More Documentations coming into view. • More infrastructural requirements. • Global Opportunities awaiting us. • India gaining image of Best source for low cost good quality generics.
CHALLENGES TODAY • Huge Investments- Bioequivalence studies, ANDA and DMF, Validations, stability studies etc • Dying API industry. • COPP’s ( Certificate of pharmaceutical product ) • Pollution norms in API industry • Yearly updations. • Implementation of GLP • Lack of Automation • Presence in regulated markets dominated by big pharma • Lack of Brand development. • Non availablity of easy bank finance. • Lack of trained and specialised manpower • Lack of confidence of government in Pharma SME’s
SUGGESTIONS • Reimbursement of bioequivalence cost atleast 50%. • Subsidised API/ ingredient units preferably PSU’s • Agreements with FDAs internationally to promote IP • Relaxation of pollution norms for the API industry • Special Incentive / subsidy for the industry on lines of tuf scheme to take care of yearly Updations • GLP upgradation subsidy shall be provided to the industry • Automation subsidy shall be provided to compete internationally. • Incentive to enter regulated markets • Marketing coops abroad should be promoted for brand development. • Banking Suggestions ( meeting with secy commerce on 13th) • More research centres like NIPER for trained manpower availaibility • Provision of a technical person in embassies
OTHER SUGGESTION • Development of clusters instead of SEZs • Plant approval cost reimbursement to be included in MAI scheme • Better incentive to bulk drugs under focus market scheme • Subsidy to units for upgradation from schedule M to CGMP.